Relationship between levodopa concentration, dyskinesias, and motor effect in parkinsonian patients: A 3-year follow-up study

被引:18
作者
Contin, M
Riva, R
Martinelli, P
Albani, F
Baruzzi, A
机构
[1] Laboratory of Neuropharmacology, Institute of Neurology, University of Bologna, Bologna
[2] Institute of Neurology, University of Bologna, 7-40123 Bologna, Via Foscolo
关键词
levodopa; Parkinson's disease; motor tests; dyskinesias; kinetic; dynamic modeling;
D O I
10.1097/00002826-199710000-00005
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
We conducted a 3-year prospective assessment of the relationship between levodopa (L-DOPA) plasma concentration and both dyskinesias and tapping motor response after a standard oral L-DOPA dose in II parkinsonian patients, Hoehn & Yahr (H & Y) stages 2-3, with L-DOPA therapeutic response complicated by involuntary movements. Over the 3-year period, duration of the tapping effect significantly decreased, while that of dyskinesias showed minor changes. Initially, the L-DOPA therapeutic response significantly outlasted the dyskinesia effect and progressively shortened to parallel the dyskinesia profile at the more advanced clinical stage. According to kinetic-dynamic modeling, L-DOPA concentrations producing 50% of maximum therapeutic and toxic effects (EC50) also changed independently. EC50 for dyskinesias did not vary significantly over time. EC50 for the tapping effect was, at the first observation, significantly lower than that of the matched value for dyskinesias and progressively rose to values similar to the EC50 for dyskinesias by the third year of follow-up, These data suggest a dissociation of the kinetic-dynamic relationship of L-DOPA motor and dyskinesia effects, possibly reflecting different cerebral handling of exogenous levodopa-derived dopamine with disease progression.
引用
收藏
页码:409 / 418
页数:10
相关论文
共 27 条
[1]   SIMPLE AND RAPID MICROMETHOD FOR THE DETERMINATION OF LEVODOPA AND 3-O-METHYLDOPA IN HUMAN-PLASMA BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY WITH COULOMETRIC DETECTION [J].
BARUZZI, A ;
CONTIN, M ;
ALBANI, F ;
RIVA, R .
JOURNAL OF CHROMATOGRAPHY, 1986, 375 (01) :165-169
[2]  
BLANCHET PJ, 1995, FUNDAM CLIN PHARM, V9, P1
[3]   Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease - A multicenter 5-year study [J].
Block, G ;
Liss, C ;
Reines, S ;
Irr, J ;
Nibbelink, D ;
Aarli, J ;
Aguilar, M ;
Ahrens, S ;
Bakheit, A ;
Baumel, B ;
Bertoni, J ;
Capildeo, R ;
CastroCaldas, A ;
Deza, L ;
Donaldson, I ;
Franck, G ;
Fusillo, J ;
Gauthier, S ;
Gershanik, O ;
Granerus, AK ;
Hauser, RA ;
Hennessey, K ;
Hutton, JT ;
Joffe, R ;
Koller, W ;
Last, B ;
LeWitt, P ;
Mamoli, B ;
Manyam, B ;
Mark, M ;
Nakano, K ;
Nausieda, P ;
Otero, E ;
Paulson, G ;
Pinter, M ;
Reich, S ;
Rodnitzky, R ;
Sage, J ;
Sampaio, C ;
Smith, B ;
Teravainen, H ;
Tetrud, J ;
Tolosa, E ;
Ulm, G ;
Valesco, F .
EUROPEAN NEUROLOGY, 1997, 37 (01) :23-27
[4]   LOW AND HIGH-DOSE BROMOCRIPTINE HAVE DIFFERENT EFFECTS ON STRIATAL DOPAMINE RELEASE - AN IN-VIVO STUDY [J].
BRANNAN, T ;
MARTINEZTICA, J ;
DIROCCO, A ;
YAHR, MD .
JOURNAL OF NEURAL TRANSMISSION-PARKINSONS DISEASE AND DEMENTIA SECTION, 1993, 6 (02) :81-87
[5]  
CALNE DB, 1994, NEUROLOGY S6, V44, P19
[6]   PHARMACODYNAMIC MODELING OF ORAL LEVODOPA - CLINICAL-APPLICATION IN PARKINSONS-DISEASE [J].
CONTIN, M ;
RIVA, R ;
MARTINELLI, P ;
CORTELLI, P ;
ALBANI, F ;
BARUZZI, A .
NEUROLOGY, 1993, 43 (02) :367-371
[7]   RESPONSE TO A STANDARD ORAL LEVODOPA TEST IN PARKINSONIAN-PATIENTS WITH AND WITHOUT MOTOR FLUCTUATIONS [J].
CONTIN, M ;
RIVA, R ;
MARTINELLI, P ;
PROCACCIANTI, G ;
CORTELLI, P ;
AVONI, P ;
BARUZZI, A .
CLINICAL NEUROPHARMACOLOGY, 1990, 13 (01) :19-28
[8]   LONGITUDINAL MONITORING OF THE LEVODOPA CONCENTRATION-EFFECT RELATIONSHIP IN PARKINSONS-DISEASE [J].
CONTIN, M ;
RIVA, R ;
MARTINELLI, P ;
CORTELLI, P ;
ALBANI, F ;
BARUZZI, A .
NEUROLOGY, 1994, 44 (07) :1287-1292
[9]  
CONTIN M, 1996, CLIN PHARMACOKINET, V6, P463
[10]   A HYPOTHESIS ON THE PATHOPHYSIOLOGICAL MECHANISMS THAT UNDERLIE LEVODOPA-INDUCED OR DOPAMINE AGONIST-INDUCED DYSKINESIA IN PARKINSONS-DISEASE - IMPLICATIONS FOR FUTURE STRATEGIES IN TREATMENT [J].
CROSSMAN, AR .
MOVEMENT DISORDERS, 1990, 5 (02) :100-108